Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Convertible Debt (2024 - 2025)

Quantum Biopharma's Convertible Debt history spans 2 years, with the latest figure at $472497.0 for Q4 2025.

  • On a quarterly basis, Convertible Debt rose 210.62% to $472497.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $472497.0, a 210.62% increase, with the full-year FY2025 number at $472497.0, up 210.62% from a year prior.
  • Convertible Debt hit $472497.0 in Q4 2025 for Quantum Biopharma, up from $429995.0 in the prior quarter.
  • Over the last five years, Convertible Debt for QNTM hit a ceiling of $472497.0 in Q4 2025 and a floor of $152113.0 in Q4 2024.